Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease ...

In fact, if we look at it through a pragmatic lens, sustainability reflects how a company does what it does, with a focus on ...

We recently compiled a list of the 10 stocks that will make you rich in 5-10 years. In this article, we are going to take a ...

A trade group representing compounding pharmacies sued the FDA for a “reckless and arbitrary” decision to remove Eli Lilly's ...

Eli Lilly’s CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as ...

Vice President Kamala Harris unveiled a new plan to cover in-home health care for seniors, a proposal she said would ease the ...

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

On Monday, Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $898.4 which represents a slight increase of $11.24 or 1.27% from the prior close of $887.16. The stock opened at $890.51 ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research ...

While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.